Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Q3 Revenues Slip 3 Percent on Lower Lab Services Sales

NEW YORK (GenomeWeb) – Transgenomic announced after the close of the market today a three percent drop in its third quarter revenues, reflecting lower sales from its contract laboratory services as it continues to refocus on its ICE-COLD PCR molecular diagnostic offerings.

"During the third quarter … we significantly advanced our ICE-COLD PCR commercialization strategy with the launch of multiple CLIA tests for cancer," such as the MX-ICP lung cancer panel, President and CEO Paul Kinnon said during a conference call following the release of the financial results. Additionally, "we signed our first commercial license for the use of ICE-COLD PCR-powered CLIA diagnostic tests and we continue to work with our pharma partners towards developing the scalable ICE-COLD PCR-based services business for the company."

During the quarter, the company also followed through on its goal of divesting non-strategic assets, Kinnon said.

In September, Transgenomic sold its ion chromatography assets to Edge BioSystems for about $2.1 million in cash. Later that month, it inked a deal to divest its Genetic Assays and Platforms business unit to Japanese biotech firm Adstec.

For the three-month period ended Sept. 30, the Omaha, Nebraska-based firm reported revenues of $4 million, down from $4.1 million in the same period the year before. Kinnon attributed the decline to $200,000 of lower contract laboratory services sales stemming from "a combination of seasonality filtrations in testing demand, as well as the transition from a focus on historical pharma services businesses to new ICE-COLD [PCR}-based pharma services." This decrease was partially offset by $100,000 in increased sales from patient-testing services.

Transgenomic's Q3 net loss from continuing operations jumped to $8.2 million, or $.62 per share, from $2.7 million, or $.41 per share, in the same period a year earlier. On a non-GAAP basis, the firm's net loss in the quarter was $1.3 million compared with $3.1 million in Q3 2014.

R&D spending the in quarter slipped to $561,000 from $641,000, while SG&A expenses fell to $3.1 million from $5.1 million.

Transgenomic finished the third quarter with cash and cash equivalents totaling $2.8 million. During Q3 the company completed a financing that raised approximately $2.7 million in net proceeds.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.